DIN 02388022 — JAKAVI 20 MG
JAKAVI is a tablet of Ruxolitinib marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Ruxolitinib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02388022
- Brand name
- JAKAVI
- Active ingredient
- Ruxolitinib
- Strength
- 20 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Janus kinase (JAK1/JAK2) inhibitor (antineoplastic agent)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Ruxolitinib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02434814 | JAKAVI | 10 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02388014 | JAKAVI | 15 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02388006 | JAKAVI | 5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |